trending Market Intelligence /marketintelligence/en/news-insights/trending/gdbp_34dywbfokrrxo-hgw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

ChangePays Although Still Underrepresented Women in the C Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Sunovion, Novartis sign license agreement for 3 pulmonary disease drugs

Sunovion Pharmaceuticals Inc. and Novartis AG signed an exclusive license agreement for U.S. commercialization rights to three approved chronic obstructive pulmonary disease drugs.

Under the deal, Sunovion will hold exclusive commercialization rights to Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler in the U.S. Novartis will continue to manufacture the three drugs.

The U.S. FDA approved Utibron Neohaler and Seebri Neohaler in 2015. Sunovion plans to bring these two drugs to market in 2017. Arcapta Neohaler was approved in the U.S. in 2011 and arrived in the market in 2012.

Sunovion Pharmaceuticals is a unit of Sumitomo Dainippon Pharma Co. Ltd.